Urinary osteoprotegerin: a potential biomarker of lupus nephritis disease activity

被引:14
|
作者
Gupta, R. [1 ]
Aggarwal, A. [1 ]
Sinha, S. [2 ]
Rajasekhar, L. [3 ]
Yadav, A. [1 ]
Gaur, P. [1 ]
Misra, R. [1 ]
Negi, V. S. [4 ]
机构
[1] Sanjay Gandhi Postgrad Inst Med Sci, Dept Clin Immunol, C Block,Rae Bareli Rd, Lucknow 226014, Uttar Pradesh, India
[2] Cent Drug Res Inst, Div Biochem, CSIR, Lucknow, Uttar Pradesh, India
[3] Nizam Inst Med Sci, Dept Rheumatol, Hyderabad, Andhra Pradesh, India
[4] JIPMER, Dept Clin Immunol, Pondicherry, India
关键词
SLE; lupus nephritis; biomarker; urinary; osteoprotegerin; ENDOTHELIAL-CELLS;
D O I
10.1177/0961203316636470
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives Urinary biomarkers may help in identification, treatment and assessment of response in patients with lupus nephritis (LN). Osteoprotegerin (OPG) is produced by the kidneys and lymphoid cells and may reflect renal disease activity better. The data on its utility are sparse. Methods Fifty-eight patients with active LN (AN), 24 with active non-renal disease (ANR) and 39 with inactive disease (ID) were included. Median disease duration was 32 (1-204) months and median age was 27 (12-50) years. AN patients were followed up every three months for one year. Urine and serum samples were collected for OPG measurement by ELISA (pg/ml) and urinary values were normalised for creatinine excretion (pg/mg). Urine samples from 24 healthy individuals (HCs) and 20 patients each of rheumatoid arthritis (RA) and diabetic nephropathy (DM) served as controls. Variables were expressed as median (range). Results At baseline, normalised urinary OPG (uOPG) was significantly higher (p<0.001) in AN (1229 (0-8577)) than ANR (236 (0-14713)), ID (463 (7-4253)), HCs (366 (120-2849)) and DM (350 (127-1577)) but it was not different from RA (1511 (122-8849)). uOPG correlated modestly with rSLEDAI (r=0.4, p<0.001) and SLEDAI (r=0.31, p<0.001) but not with serum OPG (sOPG). uOPG but not sOPG could differentiate between AN and ANR groups. In the longitudinal study, uOPG and sOPG decreased significantly with treatment at all follow-up visits but the trend of fall in sOPG was erratic. uOPG values at baseline, 3, 6, 9 and 12 months were 1229 (0-8577), 466 (3-4874), 104 (0-1598), 325 (0-4025) and 555 (6-6771) pg/mg, respectively. uOPG but not sOPG rose before conventional markers in three patients who had a relapse of LN. In two patients who developed chronic kidney disease, uOPG remained persistently high. For differentiating AN from ANR patients, uOPG performed the best on receiver operator characteristics analysis (AUC=0.72) when compared with anti-dsDNA antibodies, C3, C4 and sOPG. Conclusion uOPG is derived from kidneys and helps differentiate active SLE patients with and without LN. It shows modest correlation with disease activity and has a potential to predict poor response to therapy and relapse of LN.
引用
收藏
页码:1230 / 1236
页数:7
相关论文
共 50 条
  • [1] Urinary Osteoprotegerin As Biomarker of Lupus Nephritis Disease Activity: Cross Sectional and Longitudinal Study
    Gupta, Ranjan
    Aggarwal, Amita
    Sinha, Sudhir
    Rajasekhar, Liza
    Yadav, Akhilesh
    Gaur, Priyanka
    Misra, Ramnath
    Negi, Virsingh
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [2] Urinary ferritin creatinine ratio, a potential biomarker for lupus nephritis activity
    Lin Qi
    Jingyi Xu
    Chunshu Yang
    Xiaoyu Hou
    Pingting Yang
    Clinical Rheumatology, 2021, 40 : 143 - 149
  • [3] Urinary ferritin creatinine ratio, a potential biomarker for lupus nephritis activity
    Qi, Lin
    Xu, Jingyi
    Yang, Chunshu
    Hou, Xiaoyu
    Yang, Pingting
    CLINICAL RHEUMATOLOGY, 2021, 40 (01) : 143 - 149
  • [4] Urinary sCD25 as a biomarker of lupus nephritis disease activity
    Gupta, R.
    Yadav, A.
    Misra, R.
    Aggarwal, A.
    LUPUS, 2015, 24 (03) : 273 - 279
  • [5] Urinary VCAM-1 as a biomarker of lupus nephritis disease activity
    Eve Smith
    Rachel Corkhill
    Angela Midgley
    Louise Watson
    Caroline Jones
    Stephen Marks
    Kjell Tullus
    Clarissa Pilkington
    Michael W Beresford
    Pediatric Rheumatology, 12 (Suppl 1)
  • [6] DEVELOPING A URINARY BIOMARKER PANEL FOR MONITORING LUPUS NEPHRITIS DISEASE ACTIVITY
    Smith, Eve M. D.
    Corkhill, Rachel
    Midgley, Angela
    Watson, Louise
    Jones, Caroline
    Marks, Stephen D.
    Tullus, Kjell
    Pilkington, Clarissa
    Beresford, Michael W.
    RHEUMATOLOGY, 2015, 54 : 3 - 3
  • [7] FAR in systemic lupus erythematosus: a potential biomarker of disease activity and lupus nephritis
    Jili Xu
    Hongmei Zhang
    Nan Che
    Hengjin Wang
    Clinical and Experimental Medicine, 2023, 23 : 4779 - 4785
  • [8] FAR in systemic lupus erythematosus: a potential biomarker of disease activity and lupus nephritis
    Xu, Jili
    Zhang, Hongmei
    Che, Nan
    Wang, Hengjin
    CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 23 (08) : 4779 - 4785
  • [9] Serum Thiols as a Biomarker of Disease Activity in Lupus Nephritis
    Lalwani, Pritesh
    Bonfim Bacelar de Souza, Giselle Katiane
    Nunes de Lima, Domingos Savio
    Souza Passos, Luiz Fernando
    Boechat, Antonio Luiz
    Lima, Emerson Silva
    PLOS ONE, 2015, 10 (03):
  • [10] Urinary soluble CD163 is a good biomarker for renal disease activity in lupus nephritis
    Gupta, Ranjan
    Yadav, Akhilesh
    Aggarwal, Amita
    CLINICAL RHEUMATOLOGY, 2021, 40 (03) : 941 - 948